Life Sciences


  • ZURICH, Jan 7- Pharmaceutical companies including Switzerland's Novartis and Roche are among those developing a treatment for a specific type of lung cancer, a field that is now so crowded it may impact profits.

  • *FDA asks for more clinical trials on Lemtrada. The FDA also demanded Sanofi carry out further clinical trials using different designs and methods prior to approval, Sanofi said.

  • After a two-year investigation, a man working for a Chinese conglomerate was arrested on charges of stealing inbred corn seed from production fields in Iowa and Illinois and trying to smuggle it into China, U.S.

  • FDA panel says Merck's allergy drug effective Thursday, 12 Dec 2013 | 3:08 PM ET

    Dec 12- A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck& Co was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children. It is sold as Grazax in Europe by Merck's partner ALK Abello.

  • Dec 9- An advisory panel of medical experts on Monday voted to recommend that U.S. health regulators approve an experimental drug for ulcerative colitis and Crohn's disease developed by Takeda Pharmaceutical Co..

  • Dec 3- A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.

  • Dec 3- A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.

  • *Copies of antibody drugs start to hit market in Europe. *Norway plans studies to reassure on safety of switching. But although Europe has pioneered their path to market- approving the first biosimilar drug in 2006 and the latest, an antibody drug from U.S.-based Hospira and Celltrion of South Korea, in September- uptake has been patchy.

  • *Two or 3 more deals and Compugen could turn a profit. TEL AVIV, Nov 25- Israel's Compugen, which is trying to develop commercial drugs using computer models, says it could turn a profit if it can secure two or three more deals like its recent partnership with Bayer in immuno-oncology.

  • Nov 22- The U.S. Food and Drug Administration said on Friday it has approved a vaccine made by GlaxoSmithKline Plc for use in the event of an H5N1 bird flu epidemic. The vaccine, Pandemrix, will be added to the national stockpile and will not be available for commercial use, the FDA said.

  • The encouraging results in the early stage trial from Novavax, a biopharmaceutical company based in Rockville, Maryland, were published online in the New England Journal of Medicine.

  • *FDA questions drug trial design, says approval application premature. *FDA suggests company may need to do larger trial. Nov 12- Sarepta Therapeutics Inc lost more than 60 percent of its market value after it was advised by the U.S. health regulator to find new ways to test its flagship treatment for a rare muscle disorder.

  • ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion diagnostics unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for pharmaceutical mergers and acquisitions.

  • FRANKFURT, Nov 8- Germany's Boehringer Ingelheim, the world's largest unlisted drugmaker, is looking to expand its animal health business and is set to make an offer for poultry vaccine and feed additives maker Lohmann, two people familiar with the matter said.

  • Nov 5- Keryx Biopharmaceuticals Inc said its sole drug in development, Zerenex, proved to be effective in treating patients with chronic kidney disease who were not on dialysis. Keryx shares jumped 20 percent after the company said Zerenex met the main goal of a mid-stage trial.

  • *Sales growth in China slows to 5 pct from 15 pct in Q2. PARIS, Oct 30- French drugmaker Sanofi lowered its 2013 profit guidance for a second time after a slowdown in China, weaker generic sales in Brazil and manufacturing problems at a Toronto vaccine plant dented third-quarter results.

  • RIO DE JANEIRO, Oct 28- Brazils top biomedical research and development center announced plans on Monday to produce a combined measles and rubella vaccine for developing countries, mainly in Africa.

  • Ancient master goldsmiths were master crooks, too Friday, 26 Jul 2013 | 2:44 PM ET
    Metal workers from the time of ancient Rome were experts at shiny finishes.

    Metal workers 2,000 years ago perfected plating techniques that modern methods can't touch. Some probably coated cheap metal or wood objects in a gilded skin and sold them for big profits. NBC reports.

  • More Women Choosing Preventive Mastectomies Tuesday, 14 May 2013 | 3:34 PM ET
    Angelina Jolie

    The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.

  • Public Doubt on Bird Flu a Ghost of China's Past Tuesday, 9 Apr 2013 | 10:26 PM ET

    China has earned praise from international scientists for its handling of an outbreak of a deadly new bird flu, but a history of public health cover-ups means the Chinese public is harder to win over.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.